Evidence map›Paper›PMID 39150997›Full record

ArticleScience advances2024

SERS surgical navigation with postsurgical immunotherapy of local microtumors and distant metastases for improved anticancer outcomes.

Yu Wen, Ruoxuan Liu, Yangcenzi Xie, Xinyu Liu, Ming Li

Abstract read
In one paragraph

Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. AI-Guided SERS Defines a Pan-Cancer Diagnostic Biomarker.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yu WenSchool of Materials Science and Engineering, Central South University, Changsha, Hunan 410083, China.ORCID 0009-0006-6030-5676
Ruoxuan LiuSchool of Materials Science and Engineering, Central South University, Changsha, Hunan 410083, China.
Yangcenzi XieSchool of Materials Science and Engineering, Central South University, Changsha, Hunan 410083, China.
Xinyu LiuSchool of Materials Science and Engineering, Central South University, Changsha, Hunan 410083, China.
Ming LiSchool of Materials Science and Engineering, Central South University, Changsha, Hunan 410083, China.ORCID 0000-0002-2289-0222

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The standard of clinical care of most malignant solid cancers is surgery, followed by postsurgical adjuvant therapy, but microtumor lesions left behind after surgery and invisible distant metastases are the major reasons for treatment failure. Here, we report an integrated strategy combining surface-enhanced Raman spectroscopy (SERS) surgical navigation with postsurgical immunotherapy elicited by near-infrared II photothermal treatment and programmed death-1 antibody. The SERS surgical navigation is principally based on the multifunctional optical probes (namely, MATRA probes) integrating with T

Indexed as

ImmunotherapySpectrum Analysis, RamanAnimalsBreast NeoplasmsCell Line, TumorDisease Models, AnimalFemaleHumansMagnetic Resonance ImagingMiceMice, Inbred BALB CNeoplasm MetastasisProgrammed Cell Death 1 ReceptorSurgery, Computer-AssistedProgrammed Cell Death 1 Receptor

Identifiers

PMID39150997
PMCPMC11328900

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.